Title:
IRIDINESULFONAMIDE COMPOUND AND USE METHOD THEREOF
Document Type and Number:
WIPO Patent Application WO/2017/162156
Kind Code:
A1
Abstract:
An iridinesulfonamide compound having isocitrate dehydrogenase 1 (IDH1) inhibitory activity, pharmaceutically-acceptable salts, solvates or hydrates thereof, a pharmaceutical composition, as well as use of the compound or the pharmaceutically-acceptable salts, solvates or hydrates thereof, and the pharmaceutical composition thereof in treating IDH1 mutation-induced cancers.
Inventors:
ZHU LI (CN)
YANG YANQING (CN)
DAI LIGUANG (CN)
DUAN XIAOWEI (CN)
YANG ZHAO (CN)
ZHANG HUI (CN)
HU YUANDONG (CN)
PENG YONG (CN)
HAN YONGXIN (CN)
ZHAO RUI (CN)
TIAN XIN (CN)
WANG SHANCHUN (CN)
YANG YANQING (CN)
DAI LIGUANG (CN)
DUAN XIAOWEI (CN)
YANG ZHAO (CN)
ZHANG HUI (CN)
HU YUANDONG (CN)
PENG YONG (CN)
HAN YONGXIN (CN)
ZHAO RUI (CN)
TIAN XIN (CN)
WANG SHANCHUN (CN)
Application Number:
PCT/CN2017/077611
Publication Date:
September 28, 2017
Filing Date:
March 22, 2017
Export Citation:
Assignee:
CHIA TAI TIANQING PHARMACEUTICAL GROUP CO LTD (CN)
LIANYUNGANG RUNZHONG PHARMACEUTICAL CO LTD (CN)
CENTAURUS BIOPHARMA CO LTD (CN)
LIANYUNGANG RUNZHONG PHARMACEUTICAL CO LTD (CN)
CENTAURUS BIOPHARMA CO LTD (CN)
International Classes:
C07D203/24; A61K31/396; A61P35/00
Domestic Patent References:
| WO2012009678A1 | 2012-01-19 | |||
| WO2015010297A1 | 2015-01-29 | |||
| WO2014062511A1 | 2014-04-24 | |||
| WO2011072174A1 | 2011-06-16 | |||
| WO2012171337A1 | 2012-12-20 |
Foreign References:
| CN201180043254A | 2011-07-15 |
Other References:
BLEEKER ET AL.: "IDH1 mutations at residue p.R132(IDH1(R132)) occur frequently in high-grade gliomas but not in other solid tumors", HUM MUTAT, vol. 30, 2009, pages 7 - 11, XP002555010, DOI: doi:10.1002/humu.20937
GREEN ET AL.: "Somatic mutations of IDH1 and IDH2 in the leukemic transformation of myeloproliferative neoplasms", N ENGL J MED., vol. 362, 2010, pages 369 - 370
BLEEKER ET AL.: "IDH1 mutations at residue p.R132(IDH1(R132)) occur frequently in high-grade gliomas but not in other solid turners", HUM MUTAT, vol. 30, 2009, pages 7 - 11, XP002555010, DOI: doi:10.1002/humu.20937
MAEHR, J. CHEM. ED., vol. 62, 1985, pages 114 - 120
"Remington: The Science and Practice of Pharmacy", 2005, LIPPINCOTT, WILLIAMS & WILKINS
GREEN ET AL.: "Somatic mutations of IDH1 and IDH2 in the leukemic transformation of myeloproliferative neoplasms", N ENGL J MED., vol. 362, 2010, pages 369 - 370
BLEEKER ET AL.: "IDH1 mutations at residue p.R132(IDH1(R132)) occur frequently in high-grade gliomas but not in other solid turners", HUM MUTAT, vol. 30, 2009, pages 7 - 11, XP002555010, DOI: doi:10.1002/humu.20937
MAEHR, J. CHEM. ED., vol. 62, 1985, pages 114 - 120
"Remington: The Science and Practice of Pharmacy", 2005, LIPPINCOTT, WILLIAMS & WILKINS
Attorney, Agent or Firm:
BEIJING SUNHOPE INTELLECTUAL PROPERTY LTD. (CN)
Download PDF:
Previous Patent: METHOD FOR CONTINUOUSLY PREPARING GRAPHENE OXIDE NANOPLATELET
Next Patent: SULTAM COMPOUND AND APPLICATION METHOD THEREOF
Next Patent: SULTAM COMPOUND AND APPLICATION METHOD THEREOF